Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 13/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16675949 | 0.83 | GSK3B (0.46) | GSK3BMAPK1AAK1MAP2K4 | |
| SCHEMBL16675935 | 0.82 | GSK3B (0.49) | GSK3BMAPK1MAP2K4 | |
| SCHEMBL16675901 | 0.78 | MAPK1 (0.39) | GSK3BMAPK1 | |
| SCHEMBL16752848 | 0.77 | GSK3B (0.46) | GSK3BMAPK1MAP2K4 | |
| SCHEMBL16752841 | 0.77 | GSK3B (0.46) | GSK3BMAPK1MAP2K4 | |
| SCHEMBL16769262 | 0.77 | GSK3B (0.46) | GSK3BMAPK1MAP2K4 | |
| SCHEMBL16752844 | 0.77 | GSK3B (0.46) | GSK3BMAPK1MAP2K4 | |
| SCHEMBL18556886 | 0.76 | CCNE1 (0.38) | MAPK1 | |
| SCHEMBL16675957 | 0.76 | GSK3B (0.44) | GSK3BMAPK1AAK1 | |
| SCHEMBL16675936 | 0.75 | MAPK1 (0.41) | GSK3BMAPK1MAP2K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | ATP5F1A, ATP5F1D, ATP5F1C | GSK3B 4407/4885MAPK1 3291/4885AAK1 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.